Advertisement

Irish Journal of Medical Science

, Volume 183, Issue 2, pp 283–291 | Cite as

Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis

  • W. Chen
  • F. Li
  • C. He
  • Y. Zhu
  • W. TanEmail author
Original Article

Abstract

Objective

To conduct a meta-analysis of studies assessing abnormal glucose metabolism (AGM) prevalence among patients with primary aldosteronism (PA), calculating a combined pooled prevalence and summarizing metabolic parameters associated the pooled prevalence for comparative group.

Method

Four electronic databases (PubMed, EMBASE, Cochrane CENTRAL, and ISI-Web of Science) were systematically retrieved with no language and time restriction. Studies about elevated level of glucose metabolism in primary aldosteronism were included.

Result

Data were available in 16 studies. The pooled analysis revealed that the prevalence of elevated glucose in PA was 22.41 % (95 % CI 16.77–28.05 %), the retrospectively calculated prevalence was 31.20 % (95 % CI 15.81–46.60 %) for impaired fasting glucose, 26.19 % (95 % CI 15.17–37.21 %) for impaired glucose tolerance, 15.22 % (95 % CI 9.93–20.51 %) for diabetes mellitus. Prevalence of AGM in PA was higher than that in essential hypertension (OR = 1.55, 95 % CI 1.01–2.36, p = 0.04). From comparative groups, patients with primary aldosteronism had a lower level of insulin sensitivity indicators in comparison with normal group (p < 0.01). On the other hand, insulin resistance which presented by HOMA index was stronger in PA group than in normal control group (WMD = 0.41, 95 % CI 0.17, 0.65; p = 0.001), whereas it was weaker than that in EH group (WMD = −0.37, 95 % CI −0.62, −0.13; p = 0.003).

Conclusion

There is a significant prevalence of elevated level of glucose metabolism in patients with PA. Awareness and treatment of this pre-diabetic or diabetic state are necessary.

Keywords

Abnormal glucose metabolism Metabolic disease Primary aldosteronism Metaanalysis 

Notes

Conflict of interest

None declared.

Supplementary material

11845_2013_1007_MOESM1_ESM.doc (62 kb)
Supplementary material 1 (DOC 61 kb)
11845_2013_1007_MOESM2_ESM.doc (81 kb)
Supplementary material 2 (DOC 81 kb)

References

  1. 1.
    Conn JW (1965) Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 273(21):1135–1143PubMedCrossRefGoogle Scholar
  2. 2.
    Fallo F, Veglio F, Bertello C et al (2006) Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 91(2):454–459PubMedCrossRefGoogle Scholar
  3. 3.
    Connell JM, MacKenzie SM, Freel EM et al (2008) A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev 29(2):133–154PubMedCrossRefGoogle Scholar
  4. 4.
    Quinkler M, Born-Frontsberg E, Fourkiotis VG (2010) Comorbidities in primary aldosteronism. Horm Metab Res 42(6):429–434PubMedCrossRefGoogle Scholar
  5. 5.
    Strauch B, Widimsky J, Sindelka G et al (2003) Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol Res 52(4):503–506PubMedGoogle Scholar
  6. 6.
    Colussi G, Catena C, Lapenna R et al (2007) Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 30(9):2349–2354PubMedCrossRefGoogle Scholar
  7. 7.
    Giacchetti G, Ronconi V, Turchi F et al (2007) Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 25(1):177–186PubMedCrossRefGoogle Scholar
  8. 8.
    Kreze AS, Kreze-Spirova E, Mikulecky M (2000) Diabetes mellitus in primary aldosteronism. Bratisl Lek Listy 101(4):187–190PubMedGoogle Scholar
  9. 9.
    Choi CS, Thompson CB, Leong PK et al (2001) Short-term K(+) deprivation provokes insulin resistance of cellular K(+) uptake revealed with the K(+) clamp. Am J Physiol Renal Physiol 280(1):F95–F102PubMedGoogle Scholar
  10. 10.
    Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012PubMedCrossRefGoogle Scholar
  11. 11.
    Singer S, Das-Munshi J, Brahler E (2010) Prevalence of mental health conditions in cancer patients in acute care–a meta-analysis. Ann Oncol 21(5):925–930PubMedCrossRefGoogle Scholar
  12. 12.
    Biddle DA, Morris SB (2011) Using Lancaster’s mid-P correction to the Fisher’s exact test for adverse impact analyses. J Appl Psychol 96(5):956–965PubMedCrossRefGoogle Scholar
  13. 13.
    Lydersen S, Laake P (2003) Power comparison of two-sided exact tests for association in 2 × 2 contingency tables using standard, mid p and randomized test versions. Stat Med 22(24):3859–3871PubMedCrossRefGoogle Scholar
  14. 14.
    Brown L, Cai T, DasGupta A (2001) Interval estimation for a binomial proportion. Stat Sci 16:101–117Google Scholar
  15. 15.
    Higgins JP, Green S, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, in http://www.cochrane-handbook.org/
  16. 16.
    Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101PubMedCrossRefGoogle Scholar
  18. 18.
    Catena C, Lapenna R, Baroselli S et al (2006) Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91(9):3457–3463PubMedCrossRefGoogle Scholar
  19. 19.
    Fallo F, Della Mea P, Sonino N et al (2007) Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 20(8):855–861PubMedCrossRefGoogle Scholar
  20. 20.
    Haluzik M, Sindelka G, Widimsky J Jr et al (2002) Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. J Hum Hypertens 16(1):41–45PubMedCrossRefGoogle Scholar
  21. 21.
    Iacobellis G, Petramala L, Cotesta D et al (2010) Adipokines and cardiometabolic profile in primary hyperaldosteronism. J Clin Endocrinol Metab 95(5):2391–2398PubMedCrossRefGoogle Scholar
  22. 22.
    Ishimori M, Takeda N, Okumura S et al (1994) Increased insulin sensitivity in patients with aldosterone producing adenoma. Clin Endocrinol (Oxf) 41(4):433–438CrossRefGoogle Scholar
  23. 23.
    Matrozova J, Steichen O, Amar L et al (2009) Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 53(4):605–610PubMedCrossRefGoogle Scholar
  24. 24.
    Mosso LM, Carvajal CA, Maiz A et al (2007) A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens 25(10):2125–2130PubMedCrossRefGoogle Scholar
  25. 25.
    Reincke M, Meisinger C, Holle R et al (2010) Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s Registry. Horm Metab Res 42(6):435–439PubMedCrossRefGoogle Scholar
  26. 26.
    Widimsky J Jr, Sindelka G, Haas T et al (2000) Impaired insulin action in primary hyperaldosteronism. Physiol Res 49(2):241–244PubMedGoogle Scholar
  27. 27.
    Widimsky J Jr, Strauch B, Sindelka G et al (2001) Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus? Physiol Res 50(6):603–607PubMedGoogle Scholar
  28. 28.
    Sindelka G, Widimsky J, Haas T et al (2000) Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabet 108(1):21–25Google Scholar
  29. 29.
    Fischer E, Adolf C, Pallauf A et al. (2013) Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J Clin Endocrin Metab 98(6):2513–2520Google Scholar
  30. 30.
    Nanba K, Tamanaha T, Nakao K et al (2012) Confirmatory testing in primary aldosteronism. J Clin Endocrinol Metab 97(5):1688–1694PubMedCrossRefGoogle Scholar
  31. 31.
    Reungjui S, Pratipanawatr T, Johnson RJ et al (2008) Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia. Curr Opin Nephrol Hypertens 17(5):470–476PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Yokoshiki H, Sunagawa M, Seki T et al (1998) ATP-sensitive K + channels in pancreatic, cardiac, and vascular smooth muscle cells. Am J Physiol 274(1 Pt 1):C25–C37PubMedGoogle Scholar
  33. 33.
    Fallo F, Pilon C, Urbanet R (2012) Primary aldosteronism and metabolic syndrome. Horm Metab Res 44(3):208–214PubMedCrossRefGoogle Scholar
  34. 34.
    Underwood PC, Adler GK (2013) The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep 15(1):59–70PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Vaidya A, Underwood PC, Hopkins PN et al (2013) Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension 61(4):886–893PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2013

Authors and Affiliations

  1. 1.Department of Urology, Nanfang HospitalSouthern Medical UniversityGuangzhouChina

Personalised recommendations